Table 1. Baseline characteristics, treatments, complications of patients infected with COVID-1.
| Total (n=210) | Discharged group (n=175) | Deceased group (n=35) | P Valuea | |
| Age, median (IQR), y | 71 (67-77) | 70 (67-74) | 74 (70-82) | <0.001 |
| Sex, n (%) | ||||
| Male | 101 (48) | 79 (45) | 22 (63) | 0.056 |
| Female | 109 (52) | 96 (55) | 13 (37) | |
| Duration from onset of symptoms to admission, median (IQR), d | 10 (7-15) | 10 (7-15) | 8 (6-14) | 0.889 |
| Duration from admission to outcome, median (IQR), d | 14 (10-17) | 14 (11-17) | 9 (5-15) | <0.001 |
| Duration from onset of symptoms to outcome, median (IQR), d | 23 (17-28) | 26 (21-29) | 14 (12-24) | <0.001 |
| ICU cases, n (%) | 18/198 (9) | 2/167 (1) | 16/31 (52) | <0.001 |
| Comorbidities, n (%) | 159 (76) | 124 (71) | 35 (100) | <0.001 |
| Hypertension | 115 (55) | 97 (55) | 18 (51) | 0.664 |
| Diabetes | 38 (18) | 29 (17) | 9 (26) | 0.200 |
| Cardiovascular disease | 52 (25) | 35 (20) | 17 (49) | <0.001 |
| COPD | 3 (1) | 2 (1) | 1 (3) | 0.435 |
| Respiratory disease | 38 (18) | 20 (11) | 18 (51) | <0.001 |
| Cerebrovascular disease | 13 (6) | 6 (3) | 7 (20) | <0.001 |
| Chronic liver disease | 18 (9) | 12 (7) | 6 (17) | 0.047 |
| Digestive diseases | 21 (10) | 15 (9) | 6 (17) | 0.123 |
| Chronic kidney disease | 18 (9) | 8 (5) | 10 (29) | <0.001 |
| Malignancy | 6 (3) | 3 (2) | 3 (9) | 0.026 |
| Number of Comorbidities, n (%) | ||||
| None | 51 (24) | 51 (29) | 0 (0) | <0.001 |
| One | 56 (27) | 48 (27) | 8 (23) | |
| Two | 60 (29) | 54 (31) | 6 (17) | |
| Three | 22 (10) | 16 (9) | 6 (17) | |
| Four | 13 (6) | 4 (2) | 9 (26) | |
| Five | 4 (2) | 1 (1) | 3 (9) | |
| Six or more | 4 (2) | 1 (1) | 3 (9) | |
| Signs and symptoms, n (%) | ||||
| Fever | 151 (72) | 122 (70) | 29 (83) | 0.115 |
| Cough | 148 (71) | 118 (67) | 30 (87) | 0.031 |
| Headache | 13 (6) | 10 (6) | 3 (9) | 0.523 |
| Pharyngalgia | 20 (10) | 18 (10) | 2 (6) | 0.400 |
| Fatigue | 73 (35) | 64 (37) | 9 (26) | 0.219 |
| Anorexia | 23 (11) | 19 (11) | 4 (11) | 0.921 |
| Nausea or vomiting | 11 (5) | 9 (5) | 2 (6) | 0.890 |
| Myalgia | 12 (6) | 11 (6) | 1 (3) | 0.426 |
| Chest stuffiness | 76(36) | 65(37) | 11 (31) | 0.522 |
| Dyspnea | 17 (8) | 12 (7) | 5 (14) | 0.142 |
| Diarrhea | 24 (11) | 21 (12) | 3 (9) | 0.562 |
| First symptom, n (%) | ||||
| Fever | 107 (51) | 88 (50) | 19 (54) | <0.001 |
| Cough | 65 (31) | 55 (31) | 10 (28) | |
| Pharyngalgia | 16 (8) | 14 (8) | 2 (6) | |
| Fatigue | 9 (4) | 9 (5) | 0 (0) | |
| Anorexia | 1 (0.5) | 1 (0.5) | 0 (0) | |
| Chest tightness | 6 (3) | 4 (3) | 2 (6) | |
| Dyspnea | 1 (0.5) | 1 (0.5) | 0 (0) | |
| Diarrhea | 5 (2) | 3 (2) | 2 (6) | |
| Temperature, °C | 36.8 (36.5-37.0) | 36.7 (36.5-36.9) | 37.0 (36.5-37.8) | 0.069 |
| Heart rate, median (IQR), beat per minute | 80 (78-88) | 80 (78-86) | 85 (80-104) | 0.016 |
| Respiratory rate, median (IQR), beat per minute | 20 (20-22) | 20 (20-22) | 22 (20-26) | 0.008 |
| Mean arterial pressure, median (IQR), mm Hg | 97 (92-105) | 97 (93-104) | 100 (92-109) | 0.585 |
| Treatment, n (%) | ||||
| Antiviral therapy | 179/198 (90) | 148/167 *(89) | 31/31* (100) | 0.048 |
| Antibiotic therapy | 163/198 (82) | 133/167 (80) | 30/31 (97) | 0.022 |
| Glucocorticoid therapy | 65/198 (33) | 42/167 (25) | 23/31 (74) | <0.001 |
| Gamma globulin therapy | 37/198 (19) | 23/167 (14) | 14/31 (45) | <0.001 |
| Albumin therapy | 22/198 (11) | 10/167 (6) | 12/31 (39) | <0.001 |
| Oxygen inhalation | 133/198 (67) | 103/167 (62) | 30/31 (97) | <0.001 |
| Mechanical ventilation | 21/198 (11) | 1/167 (1) | 20/31 (66) | <0.001 |
| CRRT | 3/198 (2) | 1/167 (1) | 2/31 (7) | 0.014 |
| Complications, n (%) | ||||
| ARDS | 27 (13) | 2 (1) | 25 (71) | <0.001 |
| Acute renal failure | 4 (2) | 0 (0) | 4 (11) | <0.001 |
| Cerebral infarction | 3 (1) | 0 (0) | 3 (9) | <0.001 |
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; ICU, intensive care unit; COPD, chronic obstructive pulmonary diseases; CRRT, continuous renal replacement therapy; ARDS, acute respiratory distress syndrome. a P values indicate differences between the discharged group and the deceased group. P < 0.05 was considered statistically significant. *Record/data were missing in 8 patients in the discharged group, and in 4 patients in the deceased group regarding whether or not the patients received a treatment.